Cancer diagnosis in the Middle East is entering a new era. Instead of relying only on surgical tissue biopsies, hospitals are increasingly using a simple blood sample to uncover the genetic fingerprint of a tumor. This approach, known as liquid biopsy, is making cancer testing faster, less invasive, and more personalized for thousands of patients.
The numbers clearly reflect this transformation. The Middle East liquid biopsy market is estimated at USD 212.4 million in 2025, expected to reach USD 244.68 million in 2026, and is forecast to grow to USD 874.34 million by 2035, expanding at a 15.2% CAGR. Globally, the liquid biopsy industry is projected to increase from USD 7.08 billion in 2025 to USD 27.42 billion by 2035, highlighting the region’s growing role in precision oncology.
A Small Blood Sample Is Changing the Cancer Journey
For many cancer patients, traditional tissue biopsies are physically demanding and cannot always be repeated throughout treatment. Liquid biopsy offers a simpler alternative by detecting circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), cell-free DNA, and other biomarkers from blood.
Doctors can now monitor how tumors evolve, identify resistance to treatment, and adjust therapies much earlier. This ability to continuously monitor disease is becoming one of the strongest drivers behind the adoption of precision medicine across the Middle East.
Governments Are Investing Heavily in Genomic Medicine
The region is witnessing unprecedented investments in genomic healthcare. Saudi Arabia continues expanding its national healthcare transformation initiatives under Vision 2030, while the UAE is strengthening precision medicine through nationwide genomic programs and advanced molecular diagnostic laboratories.
Israel remains one of the world’s leading biotechnology hubs, supported by strong research institutions, startup innovation, and extensive clinical genomics capabilities. Across GCC countries, healthcare spending on advanced diagnostics continues to rise as governments prioritize early cancer detection and personalized treatment strategies.
Middle East Liquid Biopsy Market at a Glance
| Indicator | 2026 Value |
|---|---|
| Market Size | USD 244.68 Million |
| Forecast 2035 | USD 874.34 Million |
| CAGR (2026–2035) | 15.2% |
| Saudi Arabia Market Share | 38% |
| Israel Market Share | 19% |
| Blood Sample Share | 88% |
| NGS Technology Share | 61% |
| Cancer Application Share | 81% |
| Hospitals & Laboratories Share | 56% |
Saudi Arabia Leads While Israel Emerges as the Innovation Engine
Saudi Arabia accounted for 38% of the regional market in 2025, making it the largest contributor. Government investments in oncology centers, molecular laboratories, and genomic medicine have accelerated the country’s adoption of liquid biopsy technologies.
Israel represented 19% of the market and is expected to record the fastest growth through 2035. Its globally recognized biotechnology ecosystem, precision medicine research, and strong clinical trial environment continue attracting investments in advanced cancer diagnostics.
The UAE is also rapidly expanding through partnerships between healthcare providers and international diagnostic companies. Increasing cancer screening initiatives and modern laboratory infrastructure are strengthening its regional position.
Want to see the market opportunities, competitor strategies, and regional trends shaping your industry? Download a FREE customized sample report: https://www.towardshealthcare.com/download-sample/7011
Blood-Based Testing Continues to Dominate Clinical Practice
Blood remains the preferred sample type, accounting for 88% of the market because it is simple to collect, minimally invasive, and highly compatible with genomic testing platforms.
Alternative samples including urine, saliva, cerebrospinal fluid, and pleural fluid currently represent 12%, but these methods are gaining attention for specific cancer applications and future precision diagnostics.
Among biomarkers, circulating nucleic acids captured 48% of the market, while circulating tumor cells and circulating proteins each accounted for 18%, and exosomes represented 16%, with the fastest projected growth due to expanding biomarker research.
Next-Generation Sequencing Is Powering Precision Oncology
Technology remains the backbone of this market.
Multi-gene parallel analysis using next-generation sequencing (NGS) dominated with 61% market share, allowing clinicians to detect multiple cancer mutations simultaneously with exceptional sensitivity.
Meanwhile, PCR-based single gene analysis held 39%, remaining popular for targeted mutation testing because of its affordability and rapid turnaround.
Cancer applications represented 81% of all liquid biopsy usage, while reproductive health contributed 12%, driven by increasing adoption of non-invasive prenatal testing.
Hospitals and diagnostic laboratories remained the largest end users with 56% market share, followed by specialty clinics at 20% and academic research centers at 16%.
Global Diagnostic Leaders Are Expanding Their Regional Presence
Leading companies continue strengthening their footprint across the Middle East through partnerships, product launches, and precision oncology initiatives.
F. Hoffmann-La Roche offers companion diagnostics and PCR platforms widely used in oncology. Illumina remains the leader in next-generation sequencing systems supporting comprehensive genomic profiling. QIAGEN supplies sample preparation technologies and molecular assays, while Thermo Fisher Scientific provides sequencing instruments, PCR systems, reagents, and laboratory automation.
Guardant Health continues expanding blood-based comprehensive genomic profiling, and Exact Sciences is investing heavily in non-invasive cancer screening technologies. Bio-Rad Laboratories supports digital PCR applications that improve biomarker sensitivity for clinical research and oncology diagnostics.
The Next Chapter of Cancer Diagnosis Has Already Begun
The Middle East is rapidly transitioning from conventional cancer diagnostics to precision medicine powered by genomics. As governments invest in molecular healthcare, hospitals adopt advanced sequencing technologies, and biotechnology companies introduce innovative diagnostic solutions, liquid biopsy is becoming an essential part of routine oncology care.
Over the next decade, continued technological innovation, stronger healthcare infrastructure, and expanding access to personalized medicine are expected to position the Middle East as one of the fastest-growing liquid biopsy markets worldwide.
Access our exclusive, data-rich dashboard dedicated to the biotechnology industry – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a global strategy and intelligence firm focused on the biotechnology sector. We partner with biotech companies and research organizations to support innovation across drug discovery, bioprocessing, and advanced therapeutics. Through deep scientific insight and market analytics, we help accelerate development timelines, optimize R&D strategies, and translate breakthrough science into commercially viable solutions.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium